Plasma osteopontin relates to myocardial fibrosis and steatosis and to immune activation among women with HIV
Jake A. Robinson(Temple University), Tricia H. Burdo(Temple University), Mabel Toribio(Boston College), Iad Alhallak(Harvard University), Takara L. Stanley(Brigham and Women's Hospital), Thiago Quinaglia(Cardiovascular Research Center), Magid Awadalla(Massachusetts General Hospital), David A. Alagpulinsa(Harvard University), Giselle Alexandra Suero‐Abreu(Massachusetts General Hospital), Michael Jerosch‐Herold(Brigham and Women's Hospital), Ria Talathi, Michael D. Nelson(The University of Texas at Arlington), Claudia G. Durbin(Harvard University), Tomas G. Neilan(Albert Einstein College of Medicine), Lidia S. Szczepaniak(The University of Texas Southwestern Medical Center), Markella V. Zanni(Harvard University), Christopher T. Longenecker(Case Western Reserve University), Lindsay T. Fourman(Massachusetts General Hospital)
Cited by 6
Related Papers
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy
|Clinical Infectious Diseases|2001|680
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589